A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

Running, not enrolling · Phase 2

Conditions studied: Myelofibrosis

In brief

This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians' choice of treatment.

Key facts

Study ID

NCT04562870

Run by

Karyopharm Therapeutics Inc

People needed

112

Starts

2021-03-17

Expected to finish

2026-09-01

Last updated by the study team

2026-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of primary MF or post-essential thrombocythemia (ET) or post-polycythemia (PV) MF according to the 2016 World Health Organization (WHO) classification of myeloproliferative neoplasms (MPN), by the most recent local pathology report.
• Previous treatment with JAK inhibitors for at least 6 months.
• Measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥450 centimeter cube (cm\^3) by magnetic resonance imaging (MRI) or computerized tomography (CT) scan.
• Relapsed, Refractory or Intolerant to JAK inhibitors as defined as meeting one of the criteria below:
• less than (<) 35% spleen volume reduction by MRI or CT-scan (from baseline) or
• <50% decrease in spleen size by palpation (from baseline) or an increase of at least 3 cm with the spleen at least 5 cm below the left costal margin or
• Spleen volume increase greater than (>) 25% from nadir or a return to within 10% of baseline after any initial response or
• Treatment with JAK inhibitor was complicated by development of red blood cells (RBC) transfusion requirement (2 units per month for 2 month); or grade 3 thrombocytopenia, anemia, hematoma/hemorrhage; or grade 2 non-hematologic toxicity while on JAK inhibitors
• Participants ≥18 years of age.
• Eastern Cooperative Oncology Group (ECOG) less than or equal to (≤) 2.
• Platelet count ≥75*10\^9 per liter (/L).
• Absolute neutrophil count (ANC) ≥1.5*10\^9/L.
• Serum direct bilirubin ≤1.5*upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5*ULN.
• Calculated creatinine clearance (CrCl) >15 milliliter (mL)/minute (min) based on the Cockcroft and Gault formula.
• Participants with active hepatitis B virus (HBV) are eligible if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is <100 International Units (IU)/mL.
• Participants with untreated hepatitis C virus (HCV) are eligible if there is a documentation of negative viral load per institutional standard.
• Participants with history of human immunodeficiency virus (HIV) are eligible if they have cluster of differentiation 4 (CD4)+ T-cell counts ≥350 cells/microliter (mcL), negative viral load per institutional standard, and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year.
• Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective methods of contraception throughout the study and for at least 90 days after the last dose of selinexor, or for the duration as stated on the label (SmPC/USPI) for those on the comparator drug (physician's choice arm). Childbearing potential excludes: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy.
• Male participants who are sexually active must use highly effective methods of contraception throughout the study and for at least 90 days after the last dose of selinexor, or for the duration as stated on the label (SmPC/USPI) for those on the comparator drug (physician's choice arm). Male participants must agree not to donate sperm during the study treatment period.
• Participants must sign written informed consent in accordance with federal, local and institutional guidelines.

You may not qualify if…

• >5% blasts in peripheral blood or >10% blasts in bone marrow (i.e., accelerated phase).
• Previous treatment with selinexor or other exportin 1 (XPO1) inhibitors.
• Use of any standard or experimental anti-MF therapy <21 days prior to Cycle 1 Day 1 (hydroxyurea or growth factors are allowed).
• Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of selinexor (Example: vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) grade >1).
• Received strong cytochrome P450 3A (CYP3A) inhibitors ≤7 days prior to selinexor dosing or strong CYP3A inducers ≤14 days prior to selinexor dosing.
• Major surgery <28 days prior to cycle 1 day 1 (C1D1).
• Uncontrolled (ie, clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable (including parenteral).
• Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participants safety, prevent the participant from giving informed consent, or being compliant with the study procedures.
• Female participants who are pregnant or lactating.
• Participants with contraindications to use of selinexor or all the drugs intended to be used in the comparative treatment arm.

Where it is running

• The Oncology Institute of Hope and Innovation — Pasadena, California, United States
• Rocky Mountain Cancer Centers, LLP — Aurora, Colorado, United States
• Illinois Cancer Specialist — Niles, Illinois, United States
• Texas Oncology - Northeast Texas — Tyler, Texas, United States
• Peking Union Medical College Hospital — Beijing, Beijing Municipality, China
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China
• Affiliated Hospital of Nantong University — Nantong, Jiangsu, China
• The Second Affiliated Hospital of Soochow University — Suzhou, Jiangsu, China
• Suzhou University -The First Affiliated Hospital — Suzhou, Jiangsu, China
• The First Hospital of Jilin University — Changchun, Jilin, China
• Sir Run Run Shaw Hospital - Zhejiang University School of Medicine — Hangzhou, Zhejiang, China
• Institut de Cancéro-Hématologie — Brest, Brittany Region, France
• Centre Hospitalier Universitaire d'Angers (CHU Angers) — Angers, France
• University General Hospital "ATTIKON" — Athens, Attica, Greece
• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS — Meldola, Forlì-Cesena, Italy
• Università degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - Dipartimento di medicina sperimentale e clinica — Florence, Italy
• Azienda Unita Sanitaria Locale Latina - Ospedale Santa Maria Goretti — Latina, Italy
• University of Perugia Department of Medicine Hematology Section — Perugia, Italy
• Asst Settelaghi, Ospedale Di Circolo E Fondazione Macchi — Varese, Italy
• Pratia Onkologia Katowice — Katowice, Poland
• Hospital Universitario 12 de Octubre — Madrid, Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.